Pluto Biosciences, Inc

GSE136673: Regulation of DNA Methylation at Enhancers by TET2 Finetunes Gene Transcription in ER-Positive Breast Cancer Cells

Bulk RNA sequencing

Background: Aberrant DNA methylation is an epigenetic hallmark of most malignant tumors including breast cancer. However, the exact role of TET2-mediated DNA demethylation in ER-positive luminal breast cancer is not well understood. Results: Here we showed by TCGA analyses that lower TET2 mRNA expression level is associated with worse clinical outcomes (i.e., overall survival) in ER-positive but not ER-negative breast cancer. Moreover, depletion of TET2 by CRISPR/Cas9 results in increased tumorigenesis capability of MCF7 cells in vitro. Whole genome bisulfite sequencing (WGBS) analysis revealed that DNA hypermethylation (gain-of-5mC) occurs within a subgroup of enhancers including estrogen responsive element (EREs) in MCF7 cells upon TET2 depletion. ChIP-seq and RNA-seq analysis showed that TET2 depletion impairs E2-induced ER binding to these gain-of-5mC EREs and gene transcription. Conclusions: Our data suggest that TET2-mediated enhancer DNA demethylation fine-tunes ER-dependent and independent gene transcription in ER-positive breast cancer cells. SOURCE: Ruitu Lyu ( - Epigenetics lab Institutes of Biomedical Sciences Fudan University

View this experiment on Pluto Biosciences, Inc